---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-001245"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2025-01-16T23:59:59+00:00"
generated_at: "2026-05-27T23:46:50.371476+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Omeros narsoplimab sensitivity analyses confirm survival benefit; BLA resubmission planned this quarter

## Summary
- Sensitivity analyses show HR 0.24–0.42 vs external control, p-values 0.0124 to <0.00001, confirming primary endpoint robustness.
- Primary endpoint (Dec 19): HR=0.32 (95% CI 0.23–0.44), p<0.00001, over 3-fold mortality reduction in TA-TMA patients.
- Omeros targets BLA resubmission to FDA later this quarter and European MAA submission by mid-year.
- Narsoplimab has been well tolerated across trials with no safety signal of concern.

## SEC filing metadata
- accession: 0001437749-25-001245
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2025-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774925001245/0001437749-25-001245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774925001245/omer20250116c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-001245
- JSON: https://secwatch.observer/filing/0001437749-25-001245.json
- Plain text: https://secwatch.observer/filing/0001437749-25-001245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.